Nuclear Medicine Communications最新文献

{"title":"Prognostic significance of metabolic parameters from l-methyl- 11 C-methionine PET/computed tomography before postoperative adjuvant therapy in patients with glioma.","authors":"Yi Zhao, Wei Diao, Yingchun Li, Meng Zhao, Hao Lu, Xiaoxiong Wang, Ying Kou, Shirong Chen, Shiwei Qing, JingKai Yi, Dan Wang, Zhuzhong Cheng","doi":"10.1097/MNM.0000000000002128","DOIUrl":"10.1097/MNM.0000000000002128","url":null,"abstract":"<p><strong>Background: </strong>Gliomas remain challenging because of their heterogeneity and poor prognosis. This study evaluated the prognostic value of metabolic parameters derived from L-methyl- 11 C-methionine ( 11 C-MET) PET/computed tomography (CT) performed before adjuvant therapy in glioma patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 22 postoperative glioma patients who underwent 11 C-MET PET/CT before initiating adjuvant therapy. Metabolic parameters, including maximum standardized uptake value (SUV max ), mean standardized uptake value (SUV mean ), metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum tumor-to-brain ratio (TBR max ), and mean tumor-to-brain ratio (TBR mean ) were extracted, calculated, and analyzed. Receiver operating characteristic analyses were performed to determine optimal cut-off values for predicting progression-free survival (PFS). Kaplan-Meier and log-rank tests were used to evaluate the relationship between metabolic parameters and PFS.</p><p><strong>Results: </strong>All six parameters significantly predicted PFS. Optimal thresholds were SUV max (3.03), area under the curve (AUC): 0.884, SUV mean (2.84), AUC: 0.942, MTV (0.641, AUC: 0.880), TLG (2.140, AUC: 0.860), TBR max (4.64, AUC: 0.760), and TBR mean (4.50, AUC: 0.851). Patients above these cutoffs had shorter PFS (all P < 0.05). In the high-uptake groups (defined by thresholds: SUV max > 3.03, SUV mean > 2.84, MTV > 0.641, TLG > 2.140, TBR max > 4.64), the median overall survival times ranged from 263 to 279 days. In contrast, the low-uptake groups exhibited significantly longer median survival, ranging from 361 to 512 days.</p><p><strong>Conclusion: </strong>Preadjuvant 11 C-MET PET/CT provides valuable prognostic information in postoperative glioma patients. Incorporating 11 C-MET PET parameters into postoperative risk stratification may guide individualized treatment strategies and optimize clinical outcomes.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"695-703"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of acquisition timing and background uptake on [131I]meta-iodobenzylguanidine SPECT/CT interpretation in pheochromocytoma and adrenal adenoma: Erratum.","authors":"Wei Liu, Yuyue Feng, Rui Zuo, Hua Pang","doi":"10.1097/MNM.0000000000002157","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002157","url":null,"abstract":"","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":"47 6","pages":"741"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The value of preoperative 18F-fluorodeoxyglucose PET/computed tomography combined with contrast-enhanced computed tomography for assessing the resectability of pancreatic ductal adenocarcinoma.","authors":"Xuewei Wang, Tong Chen, Yanyan Xiao, Fang Liu","doi":"10.1097/MNM.0000000000002129","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002129","url":null,"abstract":"<p><strong>Objective: </strong>The objective of the study is to investigate the value of preoperative 18F-fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) combined with contrast-enhanced CT (CECT) for predicting negative resection (R0) in pancreatic ductal adenocarcinoma (PDAC).</p><p><strong>Materials and methods: </strong>This retrospective study included patients with PDAC who underwent surgical exploration/resection and received both preoperative 18F-FDG PET/CT and CECT. Resection margin status was determined histopathologically and categorized as R0 versus non-R0 (R1/R2). Clinical variables, CECT features, and PET/CT parameters [including metabolic tumor volume (MTV) and total lesion glycolysis] were compared between groups. Univariate and multivariate logistic regression analyses were performed to identify predictors of R0 resection. Diagnostic performance was evaluated using receiver operating characteristic analysis. Vascular invasion was assessed using intraoperative findings as the reference.</p><p><strong>Results: </strong>A total of 48 patients (mean age: 61 years; 31 men) were included; 27 (56.25%) achieved R0 resection. Univariate analysis identified tumor shape, tumor width, tumor height, MTV, and total lesion glycolysis as significant predictors. On multivariate analysis, MTV remained an independent predictor and showed the highest diagnostic performance for R0 resection (area under the curve = 0.854). For vascular invasion, the diagnostic accuracy of CECT and MTV was 93.0 and 84.6%, respectively.</p><p><strong>Conclusion: </strong>Preoperative 18F-FDG PET/CT provides additional value in predicting R0 resection in PDAC. MTV is an independent imaging predictor and may aid assessment of vascular invasion when interpreted in combination with CECT.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":"47 6","pages":"687-694"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary in-vivo evaluation of [ 68 Ga]Ga-FAPI-46 in a fibroblast activation protein-negative breast cancer model.","authors":"Hishar Hassan, Nur Nadhira Jafperi, Wan Hamirul Bahrin Wan Kamal, Saifullizan Mohamad, Anee Suryani Sued, Siti Aminah Muhamad, Mohd Faiz Mustaffa, Nazreen Waeleh, Hairil Rashmizal Abdul Razak, Muhamad Faiz Othman","doi":"10.1097/MNM.0000000000002131","DOIUrl":"10.1097/MNM.0000000000002131","url":null,"abstract":"<p><strong>Objectives: </strong>Fibroblast activation protein (FAP), which is abundantly expressed in cancer-associated fibroblasts, is an attractive target for tumour imaging and therapy. [ 68 Ga]Ga-FAPI-46, a gallium-68-labelled FAP inhibitor, has demonstrated favourable pharmacokinetics for PET. This study evaluated the radiolabelling efficiency, stability, and biodistribution of [ 68 Ga]Ga-FAPI-46 in a breast cancer mouse model using MCF-7 cell line, which is known to lack FAP expression.</p><p><strong>Methods: </strong>[ 68 Ga]Ga-FAPI-46 was radiolabeled directly from FAPI-46 using 68 Ga in acetate buffer and analysed for radiochemical purity (RCP) by radio-TLC. Stability at room temperature was assessed up to 5 h post-radiolabeling. Biodistribution studies were conducted in female BALB/c nude mice with MCF-7 tumours. Organ uptake was determined 1 h after injection and expressed as a percentage of injected dose per gramme of tissue (%ID/g). A comparative study between [ 68 Ga]Ga-FAPI-46 and free 68 Ga was also performed.</p><p><strong>Results: </strong>[ 68 Ga]Ga-FAPI-46 consistently achieved high RCP values (>95%, maximum 99.1%) and remained stable for up to 5 h without added radioprotectant. At 1 h, [ 68 Ga]Ga-FAPI-46 showed higher uptake in kidneys (4.15%ID/g), heart (3.59%ID/g), and liver (1.70%ID/g), and low uptake in muscle (0.31%ID/g) and bone (0.57%ID/g). Mean tumour uptake was low (0.92%ID/g), consistent with the FAP-negative status of MCF-7 cells. In contrast, free 68 Ga showed a non-specific distribution in blood (29.13%ID/g), lungs (18.50%ID/g), and bone (13.37%ID/g).</p><p><strong>Conclusion: </strong>[ 68 Ga]Ga-FAPI-46 showed efficient radiolabelling with high RCP and short-term stability. Its low accumulation in FAP-negative tumours supports tracer selectivity and provides a baseline for comparative studies in FAP-expressing tumour models.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"672-678"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147308790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of global and regional quantitative 99m Tc-3,3-diphosphono-1,2 propanodicarboxylicacid single-photon emission computed tomography with echocardiography in patients with suspected transthyretin-related cardiomyopathy.","authors":"Federico Caobelli, Cristina E Popescu, Nasir Gözlügöl, Axel Rominger, Foroud Aghapour Zangeneh, Lukas Hunziker Munsch, Nicola Ciocca, Stefan Stortecky, Stephan Dobner, Moritz Hundertmark, Christoph Gräni","doi":"10.1097/MNM.0000000000002138","DOIUrl":"10.1097/MNM.0000000000002138","url":null,"abstract":"<p><strong>Aim: </strong>Quantitative single-photon emission computed tomography (SPECT) with 99m Tc-3,3-diphosphono-1,2 propanodicarboxylicacid ([ 99m Tc]Tc-DPD) is a cornerstone in the noninvasive diagnostic workup of amyloid transthyretin-related cardiomyopathy (ATTR-CM). As diagnosis is often suspected after transthoracic echocardiography (TTE), this study aims to explore the correlations between global and regional quantitative [ 99m Tc]Tc-DPD SPECT results and TTE findings in patients with suspected ATTR-CM.</p><p><strong>Methods: </strong>Patients with suspected ATTR-CM from a single-center registry (B-CARE) were retrospectively included. All underwent quantitative [ 99m Tc]Tc-DPD SPECT/CT at the baseline examination with calculation of standardized values [maximum standardized uptake value (SUV max ) and peak SUV (SUV peak )], also normalized to bone activity (nSUV max and nSUV peak ). Data on TTE, performed within 2 weeks from the DPD scintigraphy, were also collected.</p><p><strong>Results: </strong>One hundred forty four patients were included. Of these, 99 patients were eventually diagnosed with ATTR-CM. There was a significant correlation between septal ( P  ≤ 0.001) and lateral wall thickness ( P  = 0.004) and their respective, regional SUVs ( P  < 0.001 and P  = 0.004, respectively), as well as global SUVs and maximum wall thickness ( P  = 0.024). Also, the presence of severe diastolic dysfunction correlated with nSUVs ( P  = 0.011).</p><p><strong>Conclusion: </strong>The robust correlation found between TTE-derived parameters and the corresponding [ 99m Tc]Tc-DPD SPECT SUVs supports the link between morphologic alterations and [ 99m Tc]Tc-DPD activity within the myocardium, also potentially highlighting a pathophysiological mechanism involved in the progression of ATTR-CM.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"638-643"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of volumetric 68 Ga-prostate-specific membrane antigen PET/computed tomography parameters in prostate cancer staging.","authors":"Yiğithan Okar, Hüseyin Yel","doi":"10.1097/MNM.0000000000002136","DOIUrl":"10.1097/MNM.0000000000002136","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical significance of volumetric parameters derived from 68 Ga-prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) for prostate cancer staging and their association with metastatic disease and tumor aggressiveness.</p><p><strong>Methods: </strong>This retrospective study included 206 treatment-naive patients with newly diagnosed, histopathologically confirmed prostate cancer who underwent 68 Ga-PSMA PET/CT for initial staging. Primary tumor maximum standardized uptake value (SUVmax), SUVmean, PSMA tumor volume (PSMA-TV), and total lesion PSMA (TL-PSMA) were measured using a semi-automatic segmentation method. Metastatic disease was defined by PSMA-avid nodal or distant lesions. Imaging parameters were correlated with serum prostate-specific antigen (PSA) levels, Gleason score, International Society of Urological Pathology (ISUP) grade, and D'Amico risk classification. Diagnostic performance was assessed using receiver operating characteristic analysis, and independent predictors of metastasis were evaluated using multivariable logistic regression.</p><p><strong>Results: </strong>Metastatic disease was detected in 52 of 206 patients (25.2%). TL-PSMA showed the highest diagnostic performance for predicting metastasis [area under the curve (AUC) = 0.80], followed by PSA (AUC = 0.78) and PSMA-TV (AUC = 0.77), whereas SUV-based parameters demonstrated moderate accuracy (AUC = 0.74). In multivariable analysis, TL-PSMA and PSA remained independent predictors of metastatic disease (both P  < 0.01). Volumetric and SUV-based PSMA parameters increased significantly with higher D'Amico risk category, ISUP grade, and Gleason score (all P  < 0.0001). Bilobar intraprostatic PSMA uptake was significantly associated with metastatic disease and high-risk pathological features ( P  < 0.0001).</p><p><strong>Conclusion: </strong>Volumetric 68 Ga-PSMA PET/CT parameters, particularly TL-PSMA, provide clinically relevant information for prostate cancer staging beyond conventional SUV metrics and PSA. Bilobar intraprostatic PSMA uptake is associated with aggressive disease and increased metastatic risk and may serve as a useful imaging marker in initial staging.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"732-740"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of disease distribution and maximum standardized uptake value in Langerhans cell histiocytosis: correlation with event-free and overall survival.","authors":"Zeeshan Sikandar, Aamna Hassan, Hajira Ilyas, Ayesha Zubair, Aqeela Rashid","doi":"10.1097/MNM.0000000000002130","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002130","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the prognostic value of disease distribution patterns and the baseline metabolic parameter, maximum standardized uptake value (SUVmax), on fluorine-18 fluorodeoxyglucose PET-computed tomography (¹⁸F-FDG PET-CT) in pediatric patients with Langerhans cell histiocytosis (LCH).</p><p><strong>Methodology: </strong>This retrospective study included 63 histopathologically confirmed LCH patients aged 1-18 years who underwent ¹⁸F-FDG PET-CT between August 2013 and 2025. Demographic, clinical, and imaging data were reviewed, including system involvement; risk and critical organ involvement; treatment regimens; survival time; and outcomes. Baseline SUVmax and disease distribution patterns were correlated with event-free survival (EFS) and overall survival (OS).</p><p><strong>Results: </strong>Of 63 patients, 40 (63.5%) were male and 23 (36.5%) females. Single-system involvement was observed in 32 (51%) patients, while 31 (49%) had multisystem disease. Risk-organ involvement (RO+) occurred in 12 (38.7%) multisystem patients, and critical organ involvement in 10 (32.2%). Diabetes insipidus was present in nine (14%) patients. Mean SUVmax was significantly higher in deceased patients than survivors (6.7 ± 1.8 vs. 4.7 ± 3.0; P = 0.01). Ten-year EFS was significantly better in single-system LCH than multisystem LCH (90.6 vs. 64.5%; P = 0.03) and worse in RO+ multisystem LCH than without risk-organ-involvement multisystem LCH (50 vs. 73.7%). Ten-year OS was higher in single-system LCH than multisystem LCH (93.8 vs. 74.2%; P = 0.04) and lower in RO+ multisystem LCH (50 vs. 89.5%; P = 0.01).</p><p><strong>Conclusion: </strong>Single-system LCH demonstrates significantly better survival outcomes than multisystem LCH, particularly without risk-organ involvement. Baseline SUVmax appears to be a promising prognostic imaging biomarker for predicting outcomes in pediatric LCH.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":"47 6","pages":"679-686"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of [ 18 F]fluorodeoxyglucose positron emission tomography-computed tomography metabolic radiomics in predicting response to chemotherapy in patients with non-small cell lung cancer.","authors":"Pratheek N Prasanth, Mudalsha Ravina, Ranganath T Ganga, Shobhana Raju, Amit Kumar, Rutuja Kote, Moulish Reddy, Vamshi B Naik, Sarath Krishnan, Arvind Kumar Shukla","doi":"10.1097/MNM.0000000000002127","DOIUrl":"10.1097/MNM.0000000000002127","url":null,"abstract":"<p><strong>Rationale: </strong>Accurate early prediction of chemotherapy response in non-small cell lung cancer (NSCLC) remains a clinical challenge. This study aimed to evaluate the utility of PET-based radiomic features extracted from [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) PET/computed tomography (CT) scans in predicting treatment response to platinum based chemotherapy in NSCLC patients.</p><p><strong>Methods: </strong>An ambispective observational study was conducted on 70 histopathologically confirmed NSCLC patients who underwent [ 18 F]FDG PET/CT imaging before and after chemotherapy at a tertiary cancer center. Radiomic features were extracted from the primary lesion using commercially available texture analysis software, applying a fixed standardized uptake value (SUV) threshold-based volume of interest segmentation. Conventional metabolic parameters [SUVmax, SUVmean, metabolic tumor volume (MTV), total lesion glycolysis (TLG)] and 46 radiomic features (GLRLM, NGLDM, GLCM, shape features) were analyzed. Treatment response was assessed using PERCIST criteria and patients were categorized as responders or non-responders. Statistical analysis included Mann-Whitney U test and receiver operating characteristic analysis to determine discriminatory ability of parameters.</p><p><strong>Results: </strong>Among the radiomic and metabolic parameters evaluated, only a few showed statistically significant differences between responders and non-responders. GLRLM GLNU, GLCM correlation, NGLDM contrast, and shape surface demonstrated fair predictive performance with area under the curve (AUC) values >0.7. Conventional parameters such as SUVmax and TLG did not show statistically significant differences. The optimal cutoff values, sensitivity, specificity, AUCs, and P values of significant features were also obtained.</p><p><strong>Conclusion: </strong>Select radiomic features derived from [ 18 F]FDG PET/CT scans, particularly GLNU, GLCM correlation, and NGLDM contrast, hold promise in predicting response to platinum-based chemotherapy in NSCLC. These findings suggest the potential utility of radiomics in enhancing personalized treatment strategies, although further validation is warranted.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"666-671"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of PET/computed tomography image reconstruction methods on Hopkins score in therapy response assessment of head and neck cancer patients.","authors":"Tatjana Leike, Thiago Lima, Natalia Saltybaeva, Hannes Grünig, Anna Stenger-Weisser, Ujwal Bhure, Antoine Leimgruber, Klaus Strobel","doi":"10.1097/MNM.0000000000002135","DOIUrl":"10.1097/MNM.0000000000002135","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the robustness of the Hopkins criteria score (HCS) with regards to new PET reconstruction methods in therapy response assessment of head and neck cancer after (chemo)radiotherapy [(C)RT].</p><p><strong>Methods: </strong>Maximum standardized uptake value and HCS were retrospectively assessed on fluorine-18-deoxyglucose PET/computed tomography (CT) 12 weeks after (C)RT for neck lymph nodes and the primary tumor site in 66 patients with three different reconstruction methods: standard high sensitivity reconstruction, European Association of Nuclear Medicine (EANM) Research Ltd. (EARL) reference standards 1 (EARL1) and 2 (EARL2). Histopathology (27 patients, 41%) or follow-up PET/CT 9 months after end of treatment (39 patients, 59%) served as reference standard. HCS 4 and 5 were rated as positive, 1-3 negative. The performance of HCS for all methods and intermethod concordance was assessed.</p><p><strong>Results: </strong>A total of 17 (26%) patients had tumor persistence. There was no significant difference in the performance of the reconstruction methods regarding tumor persistence. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy for PET/CT with HCS for overall tumor persistence was 77, 80, 57, 91, and 79% for sensitivity reconstruction, 65, 90, 69, 88, and 83% for EARL1 and 71, 82, 57, 89, and 79% for EARL2. The intermethod concordance of HCS across all sites demonstrated a substantial to perfect agreement with Cohens κ ranging from 0.6 to 1.0.</p><p><strong>Conclusion: </strong>PET/CT HCS for therapy response assessment in head and neck cancer serves as a robust Score independent of newer sensitive reconstructions. Despite the high NPV of PET/CT in this situation the unsatisfactory PPV remains challenging.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"715-723"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiolabeled fibroblast activation protein inhibitor PET/computed tomography imaging in invasive lobular breast cancer: a narrative review and research agenda.","authors":"Sharjeel Usmani, Ikram A Burney, Najeeb Ahmed, Khulood Al Riyami, Nisar Ahmad, Gopinath Gnanasegaran, Akram Al-Ibraheem, Arif Sheikh, Shah P Numani","doi":"10.1097/MNM.0000000000002132","DOIUrl":"10.1097/MNM.0000000000002132","url":null,"abstract":"<p><p>Fibroblast activation protein inhibitor (FAPI) PET/CT has emerged as an investigational alternative which targets cancer-associated fibroblasts, abundant in the ILC tumor stroma. This narrative review synthesizes emerging evidence on radiolabeled FAPI PET/CT in ILC and highlights potential advantages, limitations, and research gaps. A purposive literature search of SCOPUS, PubMed/MEDLINE, and Web of Science up to August 2025 identified 10 clinical publications, including three prospective studies, two retrospective comparisons, and five case reports; mixed-cohort studies were included when ILC-specific findings were extractable. Across these small, heterogeneous early studies, gallium-68 FAPI PET/CT consistently demonstrated higher tumor uptake and greater lesion conspicuity than 18 F-FDG PET/CT in several ILC-relevant scenarios, particularly infiltrative soft-tissue metastases, peritoneal and serosal involvement, and sclerotic osseous lesions. Comparative studies also reported identification of additional multifocal or multicentric primary foci and greater nodal involvement, while case reports described enhanced visualization of gastric, orbital, peritoneal, and ovarian metastases, sites often inconspicuous on 18 F-FDG PET/CT. Despite these promising findings, available evidence remains limited, predominantly observational, and lacks lesion-level histopathologic confirmation, standardized imaging protocols, and data on management impact or patient outcomes. Overall, early results suggest that gallium-68 FAPI PET/CT may offer improved lesion conspicuity in selected ILC settings; however, these observations remain hypothesis generating. Larger, multicentre prospective studies with standardized acquisition parameters, rigorous lesion validation, and clinically meaningful endpoints are required to establish the diagnostic and therapeutic relevance of FAPI PET/CT and determine whether it has a role in the routine clinical evaluation of ILC.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"612-620"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147308829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}